OLMA SEC 보고서 - Olema Pharmaceuticals, Inc.- 연례 보고, 기업 사업 설명서, 유가증권계출서

기본 통계

CIK

1750284

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Olema Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.

May 26, 2026	EX-99.1	Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer Exhibit 99.1 Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer • Study to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 • First clinical collaboration fo
May 26, 2026	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2026 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commissio
May 21, 2026	EX-99.1	Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting Exhibit 99.1 Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting • OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events • OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types • Data support the
May 21, 2026	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2026 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commissio
May 12, 2026	EX-10.4	ARTICLE 1 PREMISES, BUILDING, PROJECT, AND COMMON AREAS ARTICLE 2 LEASE TERM ARTICLE 3 BASE RENT ARTICLE 4 ADDITIONAL RENT ARTICLE 5 USE OF PREMISES ARTICLE 6 SERVICES AND UTILITIES ARTICLE 7 REPAIRS AND MAINTENANCE ARTICLE 8 ADDITIONS AND ALTERATION Exhibit 10.4 LEASE KILROY OYSTER POINT KR OYSTER POINT II, LLC, a Delaware limited liability company, as Landlord, and OLEMA PHARMACEUTICALS, INC., a Delaware corporation, as Tenant. [Olema Pharmaceuticals, Inc.] [Kilroy Oyster Point] [365 Oyster Point Blvd.] TABLE OF CONTENTS ARTICLE 1 PREMISES, BUILDING, PROJECT, AND COMMON AREAS 6 ARTICLE 2 LEASE TERM 7 ARTICLE 3 BASE RENT 7 ARTICLE 4 ADDITIONA
May 12, 2026	10-Q	Item 1. Financial Statements. Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. Item 4. Controls and Procedures. Item 1. Legal Proceedings. Item 1A. Risk Factors. Item 2. Unregistered Sales of Equity Secur Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
May 12, 2026	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commissio
May 12, 2026	EX-10.3	Olema Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Exhibit 10.3 Olema Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Olema Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (thi
May 12, 2026	EX-99.1	Olema Oncology Reports First Quarter 2026 Financial and Operating Results Exhibit 99.1 Olema Oncology Reports First Quarter 2026 Financial and Operating Results • Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients • First clinical data from OP-3136 Phase 1 study to be presented at ASCO • Ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, May
May 1, 2026	8-K	FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. On April 27, 2026, Olema Pharmaceuticals, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with KR Oyster Point II, LLC, a Delaware limited liability company (the “Landlo UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commiss
April 29, 2026	EX-99.1	Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors Exhibit 99.1 Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors SAN FRANCISCO, April 29, 2026 (GlobeNewswire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Prakash
April 29, 2026	8-K	FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 27, 2026, upon recommendation from the Nominating and Corporate Governance UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commiss
April 29, 2026	ARS	ARS ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39712 OLEMA PHARMACEUTICALS,
April 29, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
April 29, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 16, 2026	10-K	Part I Item 1. Business. Item 1B. Unresolved Staff Comments. Item 1C. Cybersecurity. Item 2. Properties. Item 3. Legal Proceedings. Item 4. Mine Safety Disclosures. Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Table of Contents ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 16, 2026	EX-21.1	Olema Pharmaceuticals, Inc. Exhibit 21.1 Olema Pharmaceuticals, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Incorporation Olema Oncology Australia PTY LTD Australia Olema Oncology International Limited Ireland
March 16, 2026	S-8	Item 3. Incorporation of Documents by Reference. Item 8. Exhibits. As filed with the Securities and Exchange Commission on March 16, 2026 Registration No.
March 16, 2026	EX-99.1	Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Exhibit 99.1 Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results • On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer • Advanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in pat
March 16, 2026	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commiss
March 16, 2026	EX-FILING FEES	Calculation of Filing Fee Tables Olema Pharmaceuticals, Inc. Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Olema Pharmaceuticals, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.0001 par value per share, reserved for future issuance pursuant to the Registrant’s 2020
March 16, 2026	EX-10.29	THIRD amendment Loan and security agreement [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
January 30, 2026	EX-10.1	OLEMA PHARMACEUTICALS, INC. EX-10.1 Exhibit 10.1 OLEMA PHARMACEUTICALS, INC. January 27, 2026 Shane Kovacs Via Email Dear Shane: This letter sets forth the terms of the separation and consulting agreement (the “Agreement”) that Olema Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. SEPARATION. Your last day of work with the Company and your employment termination date will be
January 30, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2026 Olema Pharmaceut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2026 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commi
January 12, 2026	EX-99.1	Advancing medicines for breast cancer and beyond Corporate Overview January 2025 Advancing medicines for breast cancer and beyond Corporate Overview January 2025 Forward-looking statements and legal disclaimer This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
January 12, 2026	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commi
December 11, 2025	EX-4.6	OLEMA PHARMACEUTICALS, INC. _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________ EX-4.6 Exhibit 4.6 OLEMA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF OLEMA PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associatio
December 11, 2025	EX-4.3	Olema Pharmaceuticals, Inc., Dated as of [•], 20__ Debt Securities EX-4.3 Exhibit 4.3 Olema Pharmaceuticals, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certif
December 11, 2025	EX-1.3	OLEMA PHARMACEUTICALS, INC. AMENDMENT NO. 1 TO SALES AGREEMENT EX-1.3 Exhibit 1.3 OLEMA PHARMACEUTICALS, INC. AMENDMENT NO. 1 TO SALES AGREEMENT December 11, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue, 11th Floor New York, New York 10017 Ladies and Gentlemen: Reference is made to the Sales Agreement, dated January 6, 2025 (the “Agreement”), by and between Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and TD Securities (USA) LLC (“
December 11, 2025	S-3ASR	As filed with the Securities and Exchange Commission on December 11, 2025 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on December 11, 2025 Registration No.
December 11, 2025	EX-4.7	OLEMA PHARMACEUTICALS, INC. , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF EX-4.7 Exhibit 4.7 OLEMA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF OLEMA PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banki
December 11, 2025	EX-4.5	OLEMA PHARMACEUTICALS, INC. _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________ EX-4.5 Exhibit 4.5 OLEMA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF OLEMA PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organi
December 11, 2025	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 Olema Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward
November 19, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 Olema Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Comm
November 19, 2025	424B5	10,000,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-284146 PROSPECTUS SUPPLEMENT (To Prospectus dated January 15, 2025) 10,000,000 Shares Common Stock We are offering 10,000,000 shares of our common stock. Our common stock is traded on the Nasdaq Global Select Market under the symbol “OLMA.” On November 17, 2025, the last reported sale price of our common stock on the Nas
November 19, 2025	EX-1.1	Underwriting Agreement Olema Pharmaceuticals, Inc. 10,000,000 Shares of Common Stock EX-1.1 Exhibit 1.1 EXECUTION VERSION Underwriting Agreement Olema Pharmaceuticals, Inc. 10,000,000 Shares of Common Stock November 18, 2025 TD Securities (USA) LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o TD Securities (USA) LLC 1 Vanderbilt Avenue, 11th Floor New York, New York 10017 Ladies and Gentlemen: Olema Pharmaceuticals, Inc., a Delaware corporation (th
November 18, 2025	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 Olema Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward
November 18, 2025	S-3MEF	As filed with the Securities and Exchange Commission on November 18, 2025 S-3MEF As filed with the Securities and Exchange Commission on November 18, 2025 Registration No.
November 18, 2025	424B5	Subject to completion, dated November 18, 2025 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.
November 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 Olema Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Comm
November 10, 2025	EX-99.1	Olema Oncology Reports Third Quarter 2025 Financial and Operating Results Exhibit 99.1 Olema Oncology Reports Third Quarter 2025 Financial and Operating Results • Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancer • Initiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer • Presented compelling new data fr
November 10, 2025	10-Q	Item 1. Financial Statements. Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. Item 4. Controls and Procedures. Item 1. Legal Proceedings. Item 1A. Risk Factors. Item 2. Unregistered Sales of Equity Secur Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
November 10, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Comm
October 20, 2025	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commi
October 20, 2025	EX-99.2	Advancing medicines for breast cancer and beyond Corporate Overview October 2025 Advancing medicines for breast cancer and beyond Corporate Overview October 2025 Forward-looking statements and legal disclaimer This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
October 20, 2025	EX-99.1	Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 Exhibit 99.1 Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 • Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups • Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients • In the 120 mg palazestrant cohort among p
September 18, 2025	144	144 144 0001831410 XXXXXXXX LIVE 0001750284 Olema Pharmaceuticals, Inc. 001-39712 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316 Harmon Cyrus Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 13086 108977.56 68634329 09/18/2025 NASDAQ Common 03/20/2007 Founders Shares Issuer N 10000 03/20/2007 Compensation Common 06/30/2014 Open Market Purchase Issuer N 308
September 16, 2025	144	144 144 0001831410 XXXXXXXX LIVE 0001750284 Olema Pharmaceuticals, Inc. 001-39712 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316 Harmon Cyrus Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 11914 95826.88 68634329 09/16/2025 NASDAQ Common 03/20/2007 Founder Shares Issuers N 10000 03/20/2007 Compensation Common 06/30/2014 Open Market Purchase Issuers N 191
September 2, 2025	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 02, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Com
September 2, 2025	EX-99.1	Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Exhibit 99.1 Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer • Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 • Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer s
August 11, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commis
August 11, 2025	10-Q	Item 1. Financial Statements. Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. Item 4. Controls and Procedures. Item 1. Legal Proceedings. Item 1A. Risk Factors. Item 2. Unregistered Sales of Equity Secur Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
August 11, 2025	EX-99.1	Olema Oncology Reports Second Quarter 2025 Financial and Operating Results Exhibit 99.1 Olema Oncology Reports Second Quarter 2025 Financial and Operating Results • Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclib • OPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on track to initiate in Q3 2025 • Mature data from the Ph
August 11, 2025	EX-99.2	Advancing medicines for breast cancer and beyond Corporate Overview August 2025 Advancing medicines for breast cancer and beyond Corporate Overview August 2025 Forward-looking statements and legal disclaimer This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
August 11, 2025	EX-10.1	Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 Olema Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Olema Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (thi
August 11, 2025	EX-10.2	Second Amendment to Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated June 27, 2025 Exhibit 10.2 SECOND amendment to Loan and security agreement This Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 27th day of June, 2025, by and between Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”) and OLEMA PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”). Recitals A. Bank and Borrower have entered into that ce
June 13, 2025	8-K	FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commissi
May 13, 2025	10-Q	Item 1. Financial Statements. Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. Item 4. Controls and Procedures. Item 1. Legal Proceedings. Item 1A. Risk Factors. Item 2. Unregistered Sales of Equity Secur Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
May 13, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commissio
May 13, 2025	EX-10.1	Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 Olema Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Olema Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (thi
May 13, 2025	EX-99.1	Olema Oncology Reports First Quarter 2025 Financial and Operating Results Exhibit 99.1 Olema Oncology Reports First Quarter 2025 Financial and Operating Results • Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ongoing Phase 1b/2 study • Pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast
April 28, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
April 28, 2025	ARS	ARS ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39712 OLEMA PHARMACEUTICALS,
March 18, 2025	EX-19.1	Olema Pharmaceuticals, Inc. Insider Trading Policy EXHIBIT 19.1 Olema Pharmaceuticals, Inc. Insider Trading Policy 1. Introduction During the course of your relationship with Olema Pharmaceuticals, Inc. (the “Company”), you may receive material information that is not yet public (“material nonpublic information”) about the Company or about other publicly traded companies with which the Company has business relationships. Material nonpublic informa
March 18, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Olema Pharmaceuticals, Inc.
March 18, 2025	EX-97.1	Olema Pharmaceuticals, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 Olema Pharmaceuticals, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment
March 18, 2025	S-8	As filed with the Securities and Exchange Commission on March 18, 2025 As filed with the Securities and Exchange Commission on March 18, 2025 Registration No.
March 18, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commiss
March 18, 2025	EX-10.26	Amendment Number No. 1 to the Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Oncology Limited, dated May 2, 2024 Exhibit 10.26 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment Number No. 1 to Drug Discovery Collaboration and License Agreement THIS AMENDMENT NO. 1 (the “Amendment”), is made and entered into as of the date of the last
March 18, 2025	EX-99.1	Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results Exhibit 99.1 Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results • Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with second- and third-line metastatic breast cancer on track for top-line data in 2026 • Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in patients with frontline metastatic breast cancer
March 18, 2025	EX-10.25	Clinical Trial Collaboration and Supply Agreement by and between the Registrant and Novartis Pharma AG, dated November 29, 2024. Exhibit 10.25 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (FOR PHASE III CLINICAL STUDY OF OP-1250 IN COMBINATIO
March 18, 2025	EX-21.1	Olema Pharmaceuticals, Inc. Exhibit 21.1 Olema Pharmaceuticals, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Incorporation Olema Oncology Australia PTY LTD Australia
March 18, 2025	EX-1.1	OLEMA PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENT Exhibit 1.1 OLEMA PHARMACEUTICALS, INC. $100,000,000 COMMON STOCK SALES AGREEMENT March 9, 2023 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Olema Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time d
March 18, 2025	EX-10.27	Amendment Number No. 2 to the Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Oncology Limited, dated November 15, 2024 Exhibit 10.27 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment Number No. 2 to Drug Discovery Collaboration and License Agreement THIS AMENDMENT NO. 2 (the “Amendment”), is made and entered into as of the date of the last
March 18, 2025	EX-10.18	Offer Letter by and between the Registrant and Shawnte Mitchell, dated January 27, 2025 EXHIBIT 10.18 January 27, 2025 Shawnte Mitchell EMAIL/DOCUSIGN Re: Employment Terms Dear Shawnte: Olema Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment as its Chief Legal Officer and Corporate Secretary, pursuant to the terms of this offer letter agreement (the “Agreement”). 1. Position; Duties. You will have overall responsibility for legal, corporate governance and compl
March 18, 2025	EX-10.14	Olema Pharmaceuticals, Inc. 2022 Inducement Plan, as amended December 5, 2024. Exhibit 10.14 Olema Pharmaceuticals, Inc. 2022 Inducement Plan Adopted by the Board of Directors: January 19, 2022 Amended by the Compensation Committee of the Board of Directors: December 5, 2024 Effective: January 1, 2025 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants
March 18, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 5, 2025	EX-99.1	Forward-looking statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historica Advancing medicines for breast cancer and beyond Corporate Overview March 2025 EXHIBIT 99.
March 5, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commiss
January 15, 2025	424B5	Up to $150,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-284146 PROSPECTUS Up to $150,000,000 Common Stock We have entered into a sales agreement, dated January 6, 2025, or the Sales Agreement, with TD Securities (USA) LLC, or TD Cowen, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares
January 15, 2025	424B3	27,533,038 Shares of Common Stock 424B3 1 d842969d424b3.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-284131 PROSPECTUS 27,533,038 Shares of Common Stock This prospectus relates to the resale by the selling stockholders identified in this prospectus from time to time of up to an aggregate of 27,533,038 shares of our common stock, which consists of (i) 19,928,875 shares of our common stock and (i
January 13, 2025	CORRESP	OLEMA PHARMACEUTICALS, INC. 780 Brannan Street San Francisco, California 94103 CORRESP OLEMA PHARMACEUTICALS, INC. 780 Brannan Street San Francisco, California 94103 January 13, 2025 VIA EDGAR Securities and Exchange Commission Office of Finance Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549-3010 RE: Olema Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-284146) Request for Acceleration of Effective Date Ladies and Gentlem
January 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commi
January 13, 2025	CORRESP	OLEMA PHARMACEUTICALS, INC. 780 Brannan Street San Francisco, California 94103 CORRESP OLEMA PHARMACEUTICALS, INC. 780 Brannan Street San Francisco, California 94103 January 13, 2025 VIA EDGAR Securities and Exchange Commission Office of Finance Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549-3010 RE: Olema Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-284131) Request for Acceleration of Effective Date Ladies and Gentlemen:
January 13, 2025	EX-99.1	Forward-looking statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historica Advancing medicines for breast cancer and beyond Corporate Overview January 2025 EXHIBIT 99.
January 10, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commi
January 10, 2025	EX-4.1	Form of Exchange Warrant Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER APPLICABLE SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE
January 8, 2025	LETTER	LETTER January 8, 2025 Sean Bohen, M.D., Ph.D. Chief Executive Officer and President Olema Pharmaceuticals, Inc. 780 Brannan Street San Francisco, California 94103 Re: Olema Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 3, 2025 File No. 333-284131 Dear Sean Bohen M.D., Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please r
January 8, 2025	LETTER	LETTER January 8, 2025 Sean Bohen, M.D., Ph.D. Chief Executive Officer and President Olema Pharmaceuticals, Inc. 780 Brannan Street San Francisco, California 94103 Re: Olema Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 6, 2025 File No. 333-284146 Dear Sean Bohen M.D., Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please r
January 6, 2025	S-3	As filed with the Securities and Exchange Commission on January 6, 2025 Table of Contents As filed with the Securities and Exchange Commission on January 6, 2025 Registration No.
January 6, 2025	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.6 OLEMA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF OLEMA PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] orga
January 6, 2025	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.5 OLEMA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF OLEMA PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and
January 6, 2025	EX-1.2	Sales Agreement between Olema Pharmaceuticals, Inc. and TD Securities (USA) LLC, dated January 6, 2025 Exhibit 1.2 OLEMA PHARMACEUTICALS, INC. $150,000,000 SALES AGREEMENT January 6, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Olema Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during
January 6, 2025	EX-4.3	Form of Indenture Exhibit 4.3 Olema Pharmaceuticals, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8
January 6, 2025	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.7 OLEMA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF OLEMA PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking asso
January 6, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Olema Pharmaceuticals, Inc.
January 3, 2025	S-3	As filed with the Securities and Exchange Commission on January 3, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on January 3, 2025 Registration No.
January 3, 2025	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Olema Pharmaceuticals, Inc.
December 11, 2024	SC 13G	OLMA / Olema Pharmaceuticals, Inc. / Bain Capital Life Sciences Opportunities IV, L.P. - SC 13G Passive Investment SC 13G 1 d904837dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. ) OLEMA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 pa
December 10, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 09, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Comm
December 10, 2024	EX-99.2	# # # EXHIBIT 99.2 Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium • Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer
December 10, 2024	EX-99.3	Legal disclaimer This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are Palazestrant in Combination with Ribociclib Clinical Update SABCS 2024 December 10, 2024 EXHIBIT 99.
December 10, 2024	EX-99.1	Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor EX-99.1 2 olma-ex991.htm EX-99.1 PRESS RELEASE, DATED DECEMBER 9, 2024, OF OLEMA PHARMACEUTICALS, INC. EXHIBIT 99.1 Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor • Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, CA - (GLOBE NEWSWIRE) - December 9, 2024 - Olema Pharmaceuticals, Inc. (“Olema” or “Olema
December 4, 2024	SC 13D/A	OLMA / Olema Pharmaceuticals, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 3 TO SCHEDULE 13D Activist Investment SC 13D/A 1 sc13da307422olma12042024.htm AMENDMENT NO. 3 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 pe
December 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Comm
December 2, 2024	EX-99.1	Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement EXHIBIT 99.1 Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement • Clinical trial collaboration and supply agreement enables pivotal Phase 3 OPERA-02 clinical trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer; trial initi
December 2, 2024	EX-10.1	Form of 2024 Purchase Agreement, dated November 29, 2024 (incorporated by reference to Exhibit 10.1 of the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 2, 2024). EXHIBIT 10.1 OLEMA PHARMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of November 29, 2024 (the “Effective Date”), by and among Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purc
December 2, 2024	EX-4.1	Form of Pre-Funded and Exchange Warrant EXHIBIT 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER APPLICABLE SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE
November 14, 2024	SC 13G/A	OLMA / Olema Pharmaceuticals, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-olma093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68062P106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement
November 14, 2024	SC 13G/A	OLMA / Olema Pharmaceuticals, Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427604d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68062P106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this state
November 12, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Comm
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
November 12, 2024	EX-99.1	Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update EXHIBIT 99.1 Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update • Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) • New clinical data for palazestrant (OP-1250)
September 27, 2024	EX-99.1	Advancing medicines for breast cancer and beyond Corporate Overview September 2024 Advancing medicines for breast cancer and beyond Corporate Overview September 2024 Forward-looking statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
September 27, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Com
August 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commis
August 6, 2024	EX-10.2	Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.2 Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Olema Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Com
August 6, 2024	EX-10.1	First Amendment to Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated June 28, 2024 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
August 6, 2024	EX-99.1	Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update • Presented promising interim clinical results from the ongoing study of palazestrant in combination with ribociclib at the 2024 ESMO Breast Cancer Congress. Updated results expected to be presented at a future medical meeting • Successfully completed Investigational New Drug (IND)-enabling stud
August 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
July 2, 2024	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commissi
June 14, 2024	EX-99	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 p24-2172exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without t
June 14, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commissi
June 14, 2024	SC 13G	OLMA / Olema Pharmaceuticals, Inc. / Point72 Asset Management, L.P. - OLEMA PHARMACEUTICALS INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68062P106 (CUSIP Number) June 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
June 6, 2024	SC 13D/A	OLMA / Olema Pharmaceuticals, Inc. / Logos Global Management LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 60862P106 (CUSIP Number) Derek Gould Logos Global Management LP One Letterman Drive, Building D, Suite D3-700 San Francisco, CA 94129 Tel
May 15, 2024	EX-99.1	Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress Exhibit 99.1 Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress • Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy • 85% clinical benefit
May 15, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commissio
May 15, 2024	EX-99.2	ESMO Breast Cancer 2024Palazestrant-Ribociclib Combination Interim Results May 15, 2024 ESMO Breast Cancer 2024 Palazestrant-Ribociclib Combination Interim Results May 15, 2024 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
May 8, 2024	EX-10.1	Amendment No. 2 to Amended and Restated Clinical Collaboration and Supply Agreement, by and between the Company and Novartis Institutes for BioMedical Research, Inc., dated March 22, 2024. Exhibit 10.1 Amendment No. 2 to Amended and Restated Clinical Collaboration and Supply Agreement Reference is hereby made to the Clinical Collaboration and Supply Agreement, dated July 22, 2020, as amended via the Amended and Restated Clinical Collaboration and Supply Agreement, dated January 13, 2022, and the Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement, dat
May 8, 2024	EX-99.1	Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update • Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclib • New clinical data from palazestrant-ribociclib combination study to be presented at the ESMO Breast Cancer Annual Congress 2024 in Berlin, Germany. Olema will
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
May 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commissio
April 26, 2024	ARS	ARS ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39712 OLEMA PHARMACEUTICALS,
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 22, 2024	SC 13G	OLMA / Olema Pharmaceuticals, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
March 11, 2024	S-8	As filed with the Securities and Exchange Commission on March 11, 2024 As filed with the Securities and Exchange Commission on March 11, 2024 Registration No.
March 11, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commiss
March 11, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Olema Pharmaceuticals, Inc.
March 11, 2024	EX-97.1	Incentive Compensation Recoupment Policy. Exhibit 97.1 Olema Pharmaceuticals, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment
March 11, 2024	EX-1.1	OLEMA PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENT Exhibit 1.1 OLEMA PHARMACEUTICALS, INC. $100,000,000 COMMON STOCK SALES AGREEMENT March 9, 2023 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Olema Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time d
March 11, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 11, 2024	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 Olema Pharmaceuticals, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Incorporation Olema Oncology Australia PTY LTD Australia
March 11, 2024	EX-99.1	Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update • Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 • Initiated OPERA-01 pivotal Phase 3 monotherapy trial in Q4 2023; top-line results expected in 2026 • 60-patient Phase 2
February 14, 2024	SC 13G/A	OLMA / Olema Pharmaceuticals, Inc. / Kynam Capital Management, LP - KYNAM CAPITAL MANAGEMENT, LP Passive Investment SC 13G/A 1 olmaa221424.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* OLEMA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68062P106 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the
February 14, 2024	SC 13G/A	OLMA / Olema Pharmaceuticals, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68062P106 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate
February 14, 2024	SC 13G/A	OLMA / Olema Pharmaceuticals, Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm245955d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68062P106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this stateme
February 12, 2024	SC 13G/A	OLMA / Olema Pharmaceuticals, Inc. / JANUS HENDERSON GROUP PLC - JHG PLC OWNS <5% Passive Investment SC 13G/A 1 olema123123.txt JHG PLC OWNS <5% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 3* Name of Issuer: OLEMA PHARMACEUTICALS, INC. Title of Class of Securities: Common Stock CUSIP Number: 68062P106 Date of Event Which Requires Filing of this Statement: 12/31/2023 Check the appropriate box to desig
February 12, 2024	424B3	13,211,381 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276787 PROSPECTUS 13,211,381 Shares of Common Stock This prospectus relates to the resale from time to time of up to 13,211,381 shares of our common stock held by the selling stockholders identified in this prospectus, which were issued by us in a private placement on September 12, 2023. We are not selling any shares of common stock under this
February 7, 2024	LETTER	LETTER United States securities and exchange commission logo February 7, 2024 Sean Bohen Chief Executive Officer Olema Pharmaceuticals, Inc.
February 7, 2024	CORRESP	Olema Pharmaceuticals, Inc. 780 Brannan Street San Francisco, California 94103 Olema Pharmaceuticals, Inc. 780 Brannan Street San Francisco, California 94103 February 7, 2024 VIA EDGAR Securities and Exchange Commission Office of Finance Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549-3010 RE: Olema Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-276787) Request for Acceleration of Effective Date Ladies and Gentlemen: Olema Ph
January 31, 2024	S-3	As filed with the Securities and Exchange Commission on January 31, 2024 As filed with the Securities and Exchange Commission on January 31, 2024 Registration No.
January 31, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Olema Pharmaceuticals, Inc.
January 29, 2024	SC 13G	OLMA / Olema Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment us68062p1066012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Olema Pharmaceuticals, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 68062P106 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
January 8, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commi
January 8, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commi
January 8, 2024	EX-99.1	Olema Oncology JP Morgan Conference January 2024 Olema Oncology JP Morgan Conference January 2024 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
January 8, 2024	EX-99.1	Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer Exhibit 99.1 Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling studies with goal to advance into clinical development by end of 2024 SAN FRANCISCO, Jan. 08, 2024 – Olem
January 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2024 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Commi
January 5, 2024	EX-1.1	Sales Agreement by and between Registrant and Cowen and Company, LLC, dated January 5, 2024 Exhibit 1.1 Olema Pharmaceuticals, inc. 150,000,000 SHARES COMMON STOCK SALES AGREEMENT January 5, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Olema Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to
January 5, 2024	424B5	$150,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263117 PROSPECTUS SUPPLEMENT (To prospectus dated May 2, 2022) $150,000,000 Common Stock We have entered into a sales agreement, dated January 5, 2024, or the ATM Agreement, with Cowen and Company, LLC, or TD Cowen, relating to shares of our common stock offered by this prospectus supplement and accompanying prospectus.
December 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2023 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Comm
December 6, 2023	EX-99.1	Olema SABCS December 2023 Presentation December 6, 2023 Olema SABCS December 2023 Presentation December 6, 2023 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
December 5, 2023	EX-99.1	Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies Exhibit 99.1 Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies • Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile consistent with the FDA-approved lab
December 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 05, 2023 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39712 30-0409740 (State or Other Jurisdiction of Incorporation) (Comm
November 28, 2023	SC 13D/A	OLMA / Olema Pharmaceuticals Inc / Logos Global Management LP Activist Investment SC 13D/A 1 olma13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 60862P106 (CUSIP Number) Derek Gould Logos Global Management LP One Letterman Drive, Building D, Suite D3-700 San
November 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
November 7, 2023	EX-99.1	Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update ● OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarter ● New clinical data for palazestrant (OP-1250) in combination with CDK4/6 inhibitors to be presented at the 2023 San Antonio Breast Can
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Empl
October 23, 2023	EX-99.1	Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant Exhibit 99.1 Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant · Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% · In an analysis of 49 second- and third-line patients, the median PFS was 7.2 months with a CBR of 48%; t
October 23, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Empl
October 23, 2023	EX-99.2	2 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not Exhibit 99.2 1 ESMO 2023 Palazestrant Phase 2 Monotherapy Clinical Study Results October 23, 2023 2 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking s
October 18, 2023	EX-99.1	Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors Mr. Garland brings significant industry expertise with a long track record of successful launches Exhibit 99.1 Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors Mr. Garland brings significant industry expertise with a long track record of successful launches SAN FRANCISCO, October 17, 2023 – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercial
October 18, 2023	8-K/A	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Em
October 17, 2023	EX-99.1	Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors Mr. Garland brings significant industry expertise with a long track record of successful launches Exhibit 99.1 Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors Mr. Garland brings significant industry expertise with a long track record of successful launches SAN FRANCISCO, October 17, 2023 – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercial
October 17, 2023	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Empl
October 10, 2023	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Emplo
October 10, 2023	EX-10.1	Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement, by and between the Company and Novartis Institutes for BioMedical Research, Inc., dated October 9, 2023. Exhibit 10.1 Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement Reference is hereby made to the Clinical Collaboration and Supply Agreement, dated July 22, 2020, as amended via the Amended and Restated Clinical Collaboration and Supply Agreement, dated January 13, 2022 (collectively the “Agreement”), by and between Olema Pharmaceuticals, Inc., a Delaware corporatio
October 10, 2023	EX-99.1	Olema Oncology Announces Expansion of Collaboration Agreement with Novartis Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approximately 60 patients Expanded stud Exhibit 99.1 Olema Oncology Announces Expansion of Collaboration Agreement with Novartis Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approximately 60 patients Expanded study supports the potential late-stage development of palazestrant in first-line advanced or metastatic breast cancer in combination with ri
September 14, 2023	SC 13D/A	OLMA / Olema Pharmaceuticals Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 2 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68062P106 (CUSIP Number) JAMES KR
September 13, 2023	SC 13G/A	OLMA / Olema Pharmaceuticals Inc / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68062P106 (CUSIP Number) September 12, 2023 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designa
September 5, 2023	EX-99.1	Olema Oncology Announces Combined Financing for Up to $180 Million $130 million equity private placement led by Paradigm BioCapital with participation by Lightspeed Venture Partners, Deep Track Capital, BVF Partners L.P., Cormorant Asset Management, Exhibit 99.1 Olema Oncology Announces Combined Financing for Up to $180 Million $130 million equity private placement led by Paradigm BioCapital with participation by Lightspeed Venture Partners, Deep Track Capital, BVF Partners L.P., Cormorant Asset Management, Vivo Capital, Logos Capital, and Woodline Partners LP Senior secured credit facility for up to $50 million provided by Silicon Valley Ban
September 5, 2023	EX-10.2	Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated September 5, 2023 Exhibit 10.2 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company (“Bank”) and OLEMA PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”). The parties agree as follows. The parties agree as follows: 1LOAN AND TERMS OF PAYMENT 1.1Term Loan. (a)Availabilit
September 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 Olema Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Emp
September 5, 2023	EX-10.1	Stock Purchase Agreement by and among the Registrant and the Purchasers named therein, dated September 5, 2023 Exhibit 10.1 OLEMA PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (the “Agreement”) is made as of September 5, 2023 (the “Effective Date”), by and among Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purchasers”).
August 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Employ
August 8, 2023	EX-99.1	Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update ● Initiation of OPERA-01 pivotal Phase 3 monotherapy clinical trial on track; expecting to enroll first patient in fourth quarter ● New clinical data for palazestrant (OP-1250) to be presented in the fourth quarter including both monotherapy and CDK4/6 inhibitor combination updates ● Cash, cash
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
June 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Olema Pharmaceutica UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Employe
May 11, 2023	EX-99.2	$&+&2 $$ #(("#(' ( %'(#))$# $#)#( $','8!$$ # ())"#)( " %'(#) )$ ) ( '$' %'$+($#( $ ) '+) ')( ))$# $'" -) $ BJJF3 ))"#)( # )( %'(#))$# )) ' #$) ())"#)( $ ()$'! Exhibit 99.2 - - $&+&2 $$ #(("#(' ( %'(#))$# $#)#( $','8!$$ # ())"#)( " %'(#) )$ ) ( '$' %'$+($#( $ ) '+) ')( ))$# $'" -) $ BJJF3 ))"#)( # )( %'(#))$# )) ' #$) ())"#)( $ ()$'! ) ' $','8!$$ # ())"#)(3 * $','8!$$ # ())"#)(
May 11, 2023	EX-99.1	Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study ● OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- metastatic breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction ● Overall tolerability profile of the combination is consistent with the FDA-approved label of palbociclib plus an endocrine agent ● Tumor responses have been observed in patients previously treated with CDK4/6 inhibitors SAN FRANCISCO, May 11, 2023 – Olema Pharmaceuticals, Inc.
May 11, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Employer
May 9, 2023	EX-99.1	Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update ● Initiation of first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line metastatic breast cancer planned for the second half of 2023 ● Interim Phase 2 clinical results of OP-1250 in combination with palbociclib to be presented at the 2023 ESMO Breast Cancer Annual Co
May 9, 2023	EX-10.3	Separation Agreement by and between the Registrant and Kinney Horn, dated March 8, 2023 Exhibit 10.3 March 8, 2023 Kinney Horn VIA EMAIL Dear Kinney: This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Olema Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.SEPARATION. Your employment termination date will be March 24, 2023 (the “Separation Date”). 2.ACCRUED SALARY. On the Separation Dat
May 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Employer
May 9, 2023	EX-10.2	Separation Agreement by and between the Registrant and Cyrus Harmon, dated March 21, 2023 Exhibit 10.2 March 21, 2023 Cyrus Harmon VIA EMAIL Dear Cyrus: This letter sets forth the substance of the separation agreement (the “Agreement”) that Olema Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.SEPARATION. Your employment termination date will be March 24, 2023 (the “Separation Date”). Notwithstanding the termination of your employment re
May 9, 2023	EX-10.1	Amended and Restated Clinical Collaboration and Supply Agreement by and between the Registrant and Novartis Institutes for BioMedical Research, Inc., dated January 13, 2022. Exhibit 10.1 Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDED AND RESTATED CLINICAL COLLABORATION AND SUPPLY AGREEMENT This AMENDED AND RESTATED CLINICAL COLLABORATION AND SUPPLY AGREEMENT (the “Agreement”) is made and entered into effective as of
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
April 28, 2023	ARS	ARS 81,7('67$7(6 6(&85,7,(6$1'(;&+$1*(&200,66,21 :DVKLQJWRQ'& )250.
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 tmb-20230428xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
April 10, 2023	SC 13G	OLMA / Olema Pharmaceuticals Inc / Paradigm Biocapital Advisors LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68062P106 (CUSIP Number) March 29, 2023 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate th
March 22, 2023	SC 13G/A	OLMA / Olema Pharmaceuticals Inc / Kynam Capital Management, LP - KYNAM CAPITAL MANAGEMENT, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OLEMA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68062P106 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Olema Pharmaceutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Employ
March 9, 2023	EX-99.1	Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update Exhibit 99.1 Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update ● Significant progress made advancing lead program, OP-1250, with more than 170 patients treated to date ● Initiating first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line metastatic breast cancer in the second half of 2023 ● Corporate restructuring
March 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Olema Pharmaceutica UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Employe
March 9, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Olema Pharmaceuticals, Inc.
March 9, 2023	S-8	As filed with the Securities and Exchange Commission on March 9, 2023 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No.
March 9, 2023	424B5	$100,000,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-263117 PROSPECTUS SUPPLEMENT (To prospectus dated May 2, 2022) $100,000,000 Common Stock We have entered into a sales agreement, dated March 9, 2023, or the ATM Agreement, with Oppenheimer & Co. Inc., or Oppenheimer, relating to shares of our common stock offered by this prospectus supplement and accompanying prospectus. In
March 9, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39712 OLEMA P
March 9, 2023	EX-21.1	Subsidiaries of the Registrant as of December 31, 2022. Exhibit 21.1 Olema Pharmaceuticals, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Incorporation Olema Oncology Australia PTY LTD Australia
March 9, 2023	EX-1.1	Sales Agreement by and between Registrant and Oppenheimer & Co. Inc., dated March 9, 2023. EX-1.1 2 olma-20221231xex1d1.htm EX-1.1 Exhibit 1.1 OLEMA PHARMACEUTICALS, INC. $100,000,000 COMMON STOCK SALES AGREEMENT March 9, 2023 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Olema Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows: 1.Issuance and Sale of Shares. The C
February 14, 2023	SC 13G/A	OLMA / Olema Pharmaceuticals Inc / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68062P106 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate
February 14, 2023	SC 13G/A	OLMA / Olema Pharmaceuticals Inc / Fairmount Funds Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 68062P106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule
February 10, 2023	SC 13G/A	OLMA / Olema Pharmaceuticals Inc / JANUS HENDERSON GROUP PLC - JHG PLC OWNS >5% Passive Investment SC 13G/A 1 olema02102023.txt JHG PLC OWNS >5% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: OLEMA PHARMACEUTICALS, INC. Title of Class of Securities: Common Stock CUSIP Number: 68062P106 Date of Event Which Requires Filing of this Statement: 12/31/2022 Check the appropriate box to des
February 10, 2023	SC 13G	OLMA / Olema Pharmaceuticals Inc / Kynam Capital Management, LP - KYNAM CAPITAL MANAGEMENT, LP Passive Investment SC 13G 1 olma21023.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OLEMA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68062P106 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi
February 9, 2023	SC 13G/A	OLMA / Olema Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Olema Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 68062P106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is f
February 6, 2023	SC 13G/A	OLMA / Olema Pharmaceuticals Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Olema Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 68062P106 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat
December 16, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Emp
December 16, 2022	EX-3.1	Amended and Restated Bylaws. EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS ? OF ? OLEMA PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) AS AMENDED AND RESTATED ON DECEMBER 15, 2022 ARTICLE I ? OFFICES Section 1.Registered Office. The registered office of Olema Pharmaceuticals, Inc. (the ?Corporation?) in the State of Delaware shall as set forth in the certificate of incorporation of the Corporation, as the same may be amended or res
November 14, 2022	SC 13G/A	OLMA / Olema Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* OLEMA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68062P106 (CUSIP Number) November 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Empl
November 8, 2022	EX-99.1	Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update ● Presented preliminary results from OP-1250 Phase 1/2 dose expansion study demonstrating favorable tolerability, high drug exposure, and strong anti-tumor activity at the 34th EORTC-NCI-AACR Symposium ● Initial clinical data for OP-1250 in combination with CDK 4/6 inhibitor, palbociclib, to be p
August 9, 2022	EX-99.2	Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer Exhibit 99.2 Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer SAN FRANCISCO, August 9, 2022 ? Olema Pharmaceuticals, Inc. (?Olema? or ?Olema Oncology,? Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into Phase 2 clinical developmen
August 9, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Olema Pharmaceuticals, Inc. s(Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.
August 9, 2022	EX-10.1	Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Discovery Technologies Limited, dated June 7, 2022. Exhibit 10.1 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. DRUG DISCOVERY COLLABORATION AND LICENSE AGREEMENT THIS DRUG DISCOVERY COLLABORATION AND LICENSE AGREEMENT (the ?Agreement?) is entered into as of June 7, 2022 (the ?Eff
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
August 9, 2022	EX-99.1	Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancer ? Reported progress across OP-1250 clinical development program, including selection of the recommended Phase 2 dose, initiation of Phase 2 monotherapy enrollment, and continued do
July 8, 2022	SC 13G	OLMA / Olema Pharmaceuticals Inc / BlackRock Inc. Passive Investment us68062p1066070822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Olema Pharmaceuticals, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 68062P106 - (CUSIP Number) June 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
June 23, 2022	8-K	Submission of Matters to a Vote of Security Holders ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.
June 9, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Employer
May 16, 2022	SC 13G/A	OLMA / Olema Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* OLEMA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68062P106 (CUSIP Number) May 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
May 9, 2022	EX-99.1	Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 ? ? ? Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update ? ? Phase 1/2 trial of OP-1250 continues to enroll patients in the dose expansion stage, with selection of Recommended Phase 2 Dose expected in Q2 2022 ? Phase 1b combination study with palbociclib ongoing; Additional combination trials with CDK4/6 and PI3K? inhibitors planned to initiate i
May 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Employer
May 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ? (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC.
April 28, 2022	CORRESP	April 28, 2022 CORRESP 1 filename1.htm April 28, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Olema Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-263117 Acceleration Request Requested Date:May 2, 2022 Requested Time:4:00 PM Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under t
April 28, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 tmb-20220616xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, f
April 28, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 tmb-20220428xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com
March 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Olema Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39712 30-0409740 (State or other jurisdiction (Commission (I.R.S. Employ
March 4, 2022	LETTER	LETTER United States securities and exchange commission logo March 4, 2022 John Moriarty Chief Legal Officer Olema Pharmaceuticals, Inc.
March 3, 2022	DEL AM	Olema Pharmaceuticals, Inc. 512 2nd Street, 4th Floor San Francisco, California 94107 DEL AM 1 tmb-20220303xdelam.htm DEL AM Olema Pharmaceuticals, Inc. 512 2nd Street, 4th Floor San Francisco, California 94107 March 3, 2022 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re:Olema Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-263117) Ladies and Gentlemen: Reference is made to
March 1, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables ? Form S-8 ? Olema Pharmaceuticals, Inc.
March 1, 2022	EX-4.3	Form of Indenture Exhibit 4.3 ? Olema Pharmaceuticals, Inc., Issuer ? AND [TRUSTEE], Trustee INDENTURE ? Dated as of [?], 20 Debt Securities ? ? ? ? ? ? TABLE OF CONTENTS ? ? Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and T
March 1, 2022	S-3	As filed with the Securities and Exchange Commission on February 28, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2022 Registration No.
March 1, 2022	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate ? Exhibit 4.7 ? ? OLEMA PHARMACEUTICALS, INC. ? AND ? , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT ? DATED AS OF ? ? ? ? OLEMA PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banki
March 1, 2022	EX-FILING FEES	Filing Fee Table. EX-FILING FEES 8 tmb-20220228xexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Olema Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share M
March 1, 2022	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate ? Exhibit 4.6 ? ? ? OLEMA PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ? ? ? ? ? OLEMA PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking
March 1, 2022	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate ? Exhibit 4.5 ? ? OLEMA PHARMACEUTICALS, INC. ? AND ? , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT ? DATED AS OF ? ? ? ? OLEMA PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking associ

OLMA / Olema Pharmaceuticals, Inc. - SEC 보고서, 연례 보고, 기업 사업 설명서

기본 통계

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?